Clinically Significant Drug Interactions Associated with Highly Active Antiretroviral Therapy

John J. Faragon*, PharmD, Assistant Professor of Pharmacy Practice, Albany College of Pharmacy
Clinical Pharmacist, Albany Medical College

Peter J. Piliero**, M.D., Associate Professor of Medicine, Albany Medical College, Clinical Consultant, New York State Department of Corrections

One of the most challenging issues facing providers treating patients with human immunodeficiency virus - 1 (HIV) infection is the complex problem of drug interactions associated with highly active antiretroviral therapy (HAART). Guidelines for the initial treatment of HIV infection recommend the use of at least three antiretroviral medications, each of which is associated with significant drug interactions. Further increasing the risk of drug interactions is the concurrent treatment of co-morbid disease states and therapies for prevention and/or treatment of opportunistic infections (OIs). This review focuses on the clinically significant drug interaction associated with the use of HAART.

Drug Interaction Overview

Currently, there are 21 medications from four different classes licensed in the United States for the treatment of HIV infection. Drug interactions associated with HIV medications can be broadly classified into those that alter pharmacokinetics and those that alter pharmacodynamics. Pharmacokinetic drug interactions generally result in a change in pharmacokinetic parameters, such as the area under the curve (AUC), which is a common measure of drug exposure, peak concentration (Cmax), trough concentration, or half-life. Conversely, pharmacodynamic interactions result in alterations in the pharmacologic activity of the medication; generally not causing a change in pharmacokinetic parameters. The vast majority of drug interactions encountered in HIV medicine are pharmacokinetic in nature and occur as a result of a change in the absorption, distribution, metabolism or elimination of either the HIV medication itself or the concurrently administered medication.

The cytochrome P450 (CYP450) enzyme system is responsible for the biotransformation of drugs from active to inactive metabolites that are readily excreted by the body. Given the effects of the protease inhibitor (PI) and non-nucleoside reverse transcriptase (NNRTI) class on the CYP450 system, metabolism drug interactions are most common and problematic when prescribing HAART. Though numerous isoenzymes of CYP450 have been identified, the enzymes responsible for the elimination of the majority of drugs used in HAART are CYP3A4, CYP1A2, and CYP2D6. Table 1 describes the route of elimination for HAART.

Nucleoside/nucleotide reverse transcriptase inhibitors

Drug interactions associated with the nucleoside (NRTI) and nucleotide (NtRTI) classes are minimal, as these medications are not metabolized by the CYP450 system. However, drug interactions may still occur within this class.

The currently available NRTIs and NtRTIs include zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, emtricitabine, and tenofovir. Drug interactions with zidovudine are minimal; however, one of the few pharmacodynamic interactions encountered in HIV medicine occurs with co-administered zidovudine and stavudine. Since both of these NRTIs are thymidine analogues, they can compete for the same phosphorylation site in the growing chain of HIV DNA, resulting in an antagonistic, pharmacodynamic interaction. These two agents should therefore never be combined.

The use of didanosine (ddl) is often complicated by drug interactions. The buffered tablet formulation, which contains magnesium and calcium to improve systemic absorption, interacts with certain antibiotics. As a result of the buffer chelating the antibiotic, reduced ciprofloxacin, tetracycline or doxycycline absorption may occur. To minimize this interaction, ddl should be administered at

Continued on page 2
Clinically Significant Drug Interactions...(continued from page 1)

least two hours after or six hours before the fluoroquinolone. Concurrent use of ddl-buffered tablet may also impair the absorption of the protease inhibitor (PI) atazanavir, since atazanavir requires an acidic environment for absorption. Patients should take a ddl-buffered tablet two hours after or one hour before taking atazanavir to minimize the interaction. Alternatively, use of the enteric-coated capsule formulation is an option; however, providers need to be sure that patients separate ddl and atazanavir since their dietary restrictions differ.

Probably the most significant ddl drug interaction reported occurs when didanosine is used concurrently with the NNRTI tenofovir. When enteric-coated ddl is co-administered with tenofovir, the ddl AUC increases by 60%. As a result, the recommendation for patients weighing >60kg who receive these medications concurrently is to reduce the ddl dosage to 250mg once daily. For patients weighing <60kg, no specific guidelines are available for ddl dosing; however, reduction to 200mg once daily is likely warranted. For severely underweight patients, providers may consider an even further ddl dosage reduction to 125mg once daily. Due to the magnitude of this interaction, all patients receiving concurrent tenofovir and ddl should be monitored closely for ddl-related toxicities such as pancreatitis, hyperlactatemia, and lactic acidosis, regardless of ddl dosage adjustments.

Non Nucleoside Reverse Transcriptase Inhibitors

Three NNRTIs are currently licensed for use in the US: nevirapine, delavirdine, and efavirenz. Drugs in this class are prone to drug interactions, given the fact that they are extensively metabolized via CYP3A4 and can act as either inducers or inhibitors of CYP3A4. Nevirapine and efavirenz are, in general, inducers of CYP3A4, while delavirdine is an inhibitor of CYP3A4. When one of these agents is combined with a medication that is also metabolized by CYP3A4, a drug interaction is likely to occur.

Numerous drug interactions with nevirapine have been identified. Nevirapine is a CYP3A4 inducer, therefore most drug interactions associated with it lead to an increase in metabolism and reduced concentration of the co-administered drug. For example, when nevirapine is given concurrently with methadone, withdrawal symptoms may occur as a result of reduced methadone levels. Nevirapine is added to methadone. An increase in methadone dosage may be necessary after the addition of nevirapine.

Concurrent nevirapine and oral contraceptive use may lead to contraceptive failure; therefore providers should recommend alternate methods of birth control. Rifabutin and rifampin are also potent CYP3A4 inducers and have been shown to reduce nevirapine trough concentrations by 16% and 37%, respectively. Therefore, patients on nevirapine who require anti-mycobacterial therapy should be given rifabutin to minimize the reduction in nevirapine drug levels.

Efavirenz is a potent inducer of CYP3A4 in vivo. As with nevirapine, CYP3A4 induction properties of efavirenz can result in reduced concentrations of concurrently administered drugs that are also metabolized by CYP3A4. In vitro data also suggest that efavirenz can inhibit CYP3A4. Efavirenz is therefore contraindicated with midazolam, triazolam, and ergotamine derivatives since there is a potential for increased drug concentrations of these medications and associated toxicity. Despite the inclusion of these contraindicated medications in the product labeling, no published case reports to date have either proven or refuted the validity of these interactions.

Concurrent use of the macrolide antibiotic clarithromycin should be avoided in patients receiving concurrent efavirenz. When used together, the clarithromycin AUC and Cmax decreased by 39% and 26%, respectively. Therefore, clinicians may consider using azithromycin instead, as CYP450 drug interactions are unlikely with this medication.

Similar to nevirapine, methadone withdrawal has also been reported with concurrent use of efavirenz and methadone. This is more likely to occur when adding efavirenz to a stable methadone regimen. When used together, the clarithromycin AUC and Cmax decreased by 39% and 26%, respectively. Therefore, clinicians may consider using azithromycin instead, as CYP450 drug interactions are unlikely with this medication.

Concurrent use of efavirenz with rifampin has been shown to reduce the AUC and Cmax of efavirenz by 26% and 20%, respectively. Although the clinical significance of this interaction is unknown, providers should increase the efavirenz dosage to 800mg daily to offset this interaction when using rifampin to treat

### TABLE 1: Routes of Elimination of Antiretroviral Agents and the Effect on CYP450

<table>
<thead>
<tr>
<th>Drug</th>
<th>Elimination</th>
<th>Effect on CYP450 System</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zidovudine (AZT, ZDV)</td>
<td>Hepatic metabolism with renal excretion</td>
<td>None</td>
</tr>
<tr>
<td>Didanosine (ddl)</td>
<td>Renal excretion 50%</td>
<td>None</td>
</tr>
<tr>
<td>Zalcitabine (ddC)</td>
<td>Renal excretion 70%</td>
<td>None</td>
</tr>
<tr>
<td>Stavudine (d4T)</td>
<td>Renal excretion 50%</td>
<td>None</td>
</tr>
<tr>
<td>Lamivudine (3TC)</td>
<td>Renal excretion 70%</td>
<td>None</td>
</tr>
<tr>
<td>Tenofovir (TDF)</td>
<td>Renal excretion 70-80%</td>
<td>None</td>
</tr>
<tr>
<td>Abacavir (ABC)</td>
<td>Hepatic</td>
<td>Insignificant</td>
</tr>
<tr>
<td>Emtricitabine (FTC)</td>
<td>Renal excretion 86%</td>
<td>None</td>
</tr>
<tr>
<td>Nevirapine (NVP)</td>
<td>Hepatic</td>
<td>CYP3A4 inducer</td>
</tr>
<tr>
<td>Delavirdine (DLV)</td>
<td>Hepatic</td>
<td>CYP3A4 inhibitor</td>
</tr>
<tr>
<td>Efavirenz (EFV)</td>
<td>Hepatic</td>
<td>CYP3A4 inducer/inhibitor</td>
</tr>
<tr>
<td>Saquinavir (SQV)</td>
<td>Hepatic</td>
<td>CYP3A4 inhibitor</td>
</tr>
<tr>
<td>Ritonavir (RTV)</td>
<td>Hepatic</td>
<td>CYP3A4 inhibitor</td>
</tr>
<tr>
<td>Indinavir (IDV)</td>
<td>Hepatic</td>
<td>CYP3A4 inhibitor</td>
</tr>
<tr>
<td>Nelfinavir (NFV)</td>
<td>Hepatic</td>
<td>CYP3A4 inhibitor</td>
</tr>
<tr>
<td>Amprenavir (APV)</td>
<td>Hepatic</td>
<td>CYP3A4 inhibitor</td>
</tr>
<tr>
<td>Lopinavir/ritonavir (LPV/rtv)</td>
<td>Hepatic</td>
<td>CYP3A4 inhibitor</td>
</tr>
<tr>
<td>Atazanavir (ATZ)</td>
<td>Hepatic</td>
<td>CYP3A4 inhibitor, CYP1A2</td>
</tr>
<tr>
<td>Fosamprenavir (FPV)</td>
<td>Hepatic</td>
<td>CYP3A4 inhibitor</td>
</tr>
<tr>
<td>Enfuvirtide (ENF)</td>
<td>Hepatic</td>
<td>None</td>
</tr>
</tbody>
</table>

Adapted from Reference 21.

Continued on page 4
Letter from the Editor

Dear Colleagues:

Currently, there are twenty-one medications that have been FDA approved for the treatment of HIV infection. Most HIV-infected persons who have access to treatment are experiencing highly active antiretroviral therapy- (HAART) associated immune reconstitution, are less likely to develop an opportunistic infection or malignancy, and are living longer.

However, as we wade with our patients into this ever-growing pool of medications, the risks associated with polypharmacy have increased exponentially. Drug-drug interactions have been recognized that can lead to life-threatening toxicities or subtherapeutic medication levels. Clinicians who are not knowledgeable about these potential interactions can unwittingly contribute to the development of resistant strains of HIV. Alternatively, uninformed choices can lead to the failure of opportunistic infection prophylaxis or treatment.

The onus is therefore upon us as HIV care providers to be aware of the myriad of potential adverse interactions that accompany the medications in our armamentarium. In addition, we must be cognizant of interactions that may occur with over-the-counter drugs, herbal remedies, and recreational drugs. This month’s lead article by Dr. John Faragon of Albany College of Pharmacy and Dr. Peter Piliero of Albany Medical College provides a thorough review of the clinically significant drug interactions associated with HAART. This month’s HIV 101 addresses drug interactions that can occur with the concurrent use HAART and methadone.

Next month we will bring you an update on Tuberculosis and a Spotlight on the growing role of electronic medical records in the management of chronic diseases, with a focus on products that are currently being used in the correctional setting.

As always, we welcome your feedback and suggestions. We value the collaborative relationship that we have developed with you, our readers and colleagues in correctional health care. It is our sincere hope that HEPP Report’s first issue of 2004 meets your expectations, and that we continue to serve as a useful resource to you throughout the coming year.

Sincerely,

Joseph Bick, MD
Julia Noguchi, MA

Subscribe to HEPP Report

Fax to 617-770-3339 for any of the following: (please print clearly or type)

___ Yes, I would like to add/update/correct (circle one) my contact information for my complimentary subscription of HEPP Report fax/email newsletter.

___ Yes, I would like to sign up the following colleague to receive a complimentary subscription of HEPP Report fax/email newsletter.

___ Yes, I would like my HEPP Report to be delivered in the future as an attached PDF file in an email (rather than have a fax).

NAME: __________________________ FACILITY: __________________________

CHECK ONE:

☐ Physician       ☐ Physician Assistant       ☐ Nurse/Nurse Practitioner
☐ Pharmacist     ☐ Medical Director/Administrator       ☐ Nurse Administrator
☐ Other

ADDRESS: __________________________ CITY: __________________________ STATE: ___ ZIP: __________

FAX: __________________________ PHONE: __________________________

EMAIL: __________________________
Clinically Significant Drug Interactions...(continued from page 2)

tuberculosis.15 Another alternative would be to use rifabutin instead of rifampin; current guidelines suggest that the rifabutin dose be increased to 450 mg daily and the dosage of efavirenz should remain at 600mg once daily.

Unlike efavirenz and nevirapine, delavirdine is a potent inhibitor of CYP3A4. As a result, concurrent administration of drugs metabolized by the same isoenzyme are likely to cause increased drug levels and potential drug toxicity. Drugs that are likely to have increased serum levels when used concurrently with delavirdine include alprazolam, midazolam, triazolam, sildenafil, ergot alkaloid derivatives, nifedipine, and the HMGCoA-reductase inhibitors simvastatin and lovastatin.16 Concurrent use of these medications should be avoided in patients receiving delavirdine.

The medications rifampin and rifabutin have also been shown to reduce the AUC of delavirdine by 96% and 80%, respectively. Current guidelines for ART recommend that these medications be avoided in patients receiving concurrent delavirdine due to the high risk for development of resistance and virologic failure.15,16

Other potential drug interactions with the entire NNRTI class include the anticonvulsants phenytoin, carbamazepine, and phenobarbital. Since these medications induce the CYP450 system, reduced drug levels of delavirdine, efavirenz, and nevirapine may occur and should be avoided if possible. A potential alternative is the medication levetiracetam and may be considered with concurrent ARV treatment, as it does not have significant CYP450 interactions. When prescribing levetiracetam, the patient should have close follow-up with a neurologist.

In treating patients who have failed their first regimen, or are in deeper salvage therapy, providers may be forced to use NNRTIs and PIs together. Providers need to be cognizant of dosage changes required when using these two classes concurrently, given the effect of both classes on the CYP3A4 system. As the NNRTIs efavirenz and nevirapine are known inducers of the CYP3A4 system, significant reductions in PI levels may occur when using these drugs concurrently. For example, when using efavirenz or nevirapine with indinavir or lopinavir/ritonavir, the AUC of the PIs are reduced by about 33%. To offset this interaction, providers need to increase the PI dosage: for indinavir the dosage needs to be increased to 1000mg every eight hours, and for lopinavir/ritonavir, the dosage needs to be increased to four capsules (533mg/133mg) twice daily.17,18 Conversely, as delavirdine is a potent inhibitor of CYP3A4, concurrent use with indinavir requires a dosage reduction to 600 mg every eight hours.17 No data exist that describe the pharmacokinetic interaction between lopinavir/ritonavir and delavirdine.

Concurrent use of the two new PIs atazanavir and fosamprenavir with either efavirenz or nevirapine also result in reduction in PI levels. However, instead of dosage adjustments, data suggest that the addition of ritonavir to these PIs is a viable option to offset the reductions in PI drug level. For example, during concurrent use of atazanavir and efavirenz, AUC was reduced by about 74%.19 To offset the interaction, providers need to reduce the atazanavir dosage to 300mg once daily and also add ritonavir 100mg once daily. When boosted fosamprenavir once daily is used concurrently with efavirenz, fosamprenavir should be given 1400mg with 300mg of ritonavir once daily or fosamprenavir 700mg with ritonavir 100mg both twice daily.20 Though data evaluating the drug interaction between nevirapine and either atazanavir or fosamprenavir are unavailable, expert opinion suggests that the same dosage adjustments should be made, given the similarity in efavirenz and nevirapine metabolism. Data combining these medications with delavirdine is not available. See Table 2 for a summary of dosage recommendations with select PI and NNRTI combinations.

Protease Inhibitors

All PIs are potent inhibitors of CYP3A4, and as a result, drug interactions are often very complex. As a result of CYP3A4 inhibition, medication levels of agents also metabolized by the same isoenzyme have the potential to be markedly increased by the PI, potentially leading to an increased incidence of adverse effects. PIs have differing affinities for the CYP3A4 isoenzyme. The most potent inhibitor of CYP3A4 is ritonavir, whereas the least potent is saquinavir; CYP3A4 inhibition associated with indinavir, nelfinavir, and amprrenavir, and atazanavir tends to be intermediate.21 Ritonavir is often the most likely medication in the PI class to cause drug interactions because in addition to its CYP3A4 inhibition, it also inhibits CYP2D6 and induces CYP1A2 and CYP2C9. However, ritonavir is often used to enhance the pharmacokinetic parameters of co-administered PIs due to its potent inhibition of their metabolism by CYP3A4.

Numerous medications should be avoided when using PI-based therapy. The benzodiazepines midazolam and triazolam are contraindicated, as these medications are metabolized by CYP3A4 and their concentrations can be markedly increased, resulting in prolonged sedation. Though the benzodiazepine alprazolam may also be increased by concurrent PI therapy, low doses may be acceptable to use. Other potential alternatives to these agents include lorazepam, oxazepam, or temazepam, as these medications are not metabolized by CYP450.21

Hyperlipidemia is a common occurrence with

| TABLE 2: Dosing Recommendations when Combining Non Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors |
|-------------------------------------------------|--------------------------------------------------|
| Protease Inhibitor/Non Nucleoside Reverse Transcriptase Inhibitor Combination | Dosage recommendation |
| Indinavir with efavirenz or nevirapine | Standard dose for efavirenz and nevirapine. Increase indinavir dosage to 1000mg every eight hours. |
| Indinavir with delavirdine | Standard dose delavirdine. Decrease indinavir dosage to 600mg every eight hours. |
| Amprenavir with efavirenz or nevirapine | Standard dose for efavirenz and nevirapine. Increase amprenavir dosage to 1200mg three times daily. |
| Lopinavir/ritonavir with efavirenz or nevirapine | Standard dose for efavirenz and nevirapine. Increase lopinavir/ritonavir dose to 533mg/133mg (four capsules) twice daily. |
| Atazanavir with efavirenz (and probably nevirapine, though dosages have not been established with nevirapine) | Standard dose for efavirenz and probably nevirapine. Give atazanavir 300mg once daily AND add ritonavir 100mg once daily |
| Fosamprenavir with efavirenz (and probably nevirapine, though dosages have not been established with nevirapine) | Standard dose for efavirenz and probably nevirapine. If using fosamprenavir with ritonavir twice daily, give fosamprenavir 700mg with ritonavir 100mg twice daily. If using fosamprenavir with ritonavir once daily, give fosamprenavir 1400mg with ritonavir 300mg once daily. |

Data from references 17-21.
PI therapy, though it may also be associated with stavudine and efavirenz. As a result, providers often treat hyperlipidemia with either fibrin acid derivatives or with HMG-CoA reductase inhibitors, also referred to as statins. Although drug interactions with the fibrin acid derivatives have not been identified, the use of certain statins is contraindicated with the use of a PI. The two most problematic statins are simvastatin and lovastatin, as these agents are extensively metabolized via CYP3A4. When used concurrently with PIs, these statin levels are markedly increased, placing the patient at risk for myopathy, rhabdomyolysis, and possibly renal failure and death. Statins that are considered safe include pravastatin or fluvastatin, as they have minimal effect on CYP450, therefore reducing the risk of drug interactions. Another potential option is atorvastatin, however CYP3A4 is involved with its metabolism. Use of atorvastatin with PI therapy should be done only with the lowest available dosages and with close follow-up for potential hepatotoxicity and muscle toxicity. The newest statin, rosuvastatin, cannot be recommended as no drug interaction studies exist evaluating concurrent PI use.

The use of PIs (and NNRTIs) often complicates the treatment of mycobacterial infections such as tuberculosis and MAC because rifampin and rifabutin are potent inducers of CYP3A4, leading to significant reductions in PI levels. However, rifampin is much more problematic, as it is a more potent inducer of CYP3A4 compared to rifabutin. Therefore, concurrent use of rifampin with PI regimens that do not include ritonavir is generally contraindicated due to risks of subtherapeutic levels of PIs that can result in either virologic failure or resistance.

Herbal therapy is common in the setting of HIV infection. Oftentimes, herbal therapies have not been studied with concurrent HAART, and therefore their use should be discouraged unless data evaluating their effect on HAART are available. St. John's wort and garlic supplementation significantly reduce the levels of the PIs indinavir and saquinavir soft gel capsule, respectively. Since other PIs and NNRTIs are also metabolized by CYP3A4, similar interactions with other medications in these classes would be expected. Therefore, patients should be encouraged to avoid St. John's wort, garlic supplements, and other herbal therapies that have not been formally studied with PIs. The herbal therapy milk thistle, often used as a hepatoprotectant, has been shown to have minimal effects on the PI indinavir. Providers choosing to offer milk thistle to patients may be able to do so safely with PI- and NNRTI-based therapies;

<table>
<thead>
<tr>
<th>Drug</th>
<th>Interaction</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ergot alkaloids such as</td>
<td>Impaired hepatic metabolism</td>
<td>Avoid concurrent use with</td>
</tr>
<tr>
<td>dihydroergotamine, ergonovine,</td>
<td>from PI reported to increase</td>
<td>PI therapy. Consider alternative</td>
</tr>
<tr>
<td>ergotamine, methylergonovine</td>
<td>risk of ergotamine toxicity</td>
<td>drugs such as sumatriptan.</td>
</tr>
<tr>
<td>Simvastatin, lovastatin, high dose atorvastatin</td>
<td>HMG CoA reductase inhibitor levels markedly increased</td>
<td>Select pravastatin or low dose atorvastatin during concurrent PI therapy as alternatives.</td>
</tr>
<tr>
<td>Phenytoin, carbamazepine, phenobarbital</td>
<td>Potential for increased metabolism of PI, leading to virologic failure</td>
<td>Avoid concurrent use if possible. Consider alternative anticonvulsant during PI therapy.</td>
</tr>
<tr>
<td>Alprazolam, midazolam, triazolam</td>
<td>Potential for prolonged or increased sedation or respiratory depression</td>
<td>Avoid concurrent use. Consider zolpidem or lorazepam.</td>
</tr>
<tr>
<td>GI motility agents</td>
<td>Cisapride</td>
<td>Contraindicated due to marked increase in cisapride levels and potential for QT prolongation</td>
</tr>
<tr>
<td>St. John's wort</td>
<td>Significant decrease in PI (IDV studied) levels, potentially leading to virologic failure or resistance</td>
<td>Avoid concurrent use during PI therapy.</td>
</tr>
<tr>
<td>Garlic</td>
<td>Significant decrease in PI (SQV studied) levels, potentially leading to virologic failure or resistance</td>
<td>Avoid concurrent use with PI therapy.</td>
</tr>
<tr>
<td>Pimozide</td>
<td>Potential increased risk of cardiac toxicity with concurrent ritonavir use</td>
<td>Avoid concurrent use with ritonavir-based regimens, including lopinavir/ritonavir.</td>
</tr>
<tr>
<td>Rifampin</td>
<td>Significant decrease in PI concentrations, potentially leading to virologic failure May use with full dose ritonavir</td>
<td>Consider rifabutin as an alternative.</td>
</tr>
<tr>
<td>Amiodarone, propafenone, bepridil, quinidine, flecainide</td>
<td>Potential increased risk for severe cardiac arrhythmias with concurrent ritonavir use</td>
<td>Avoid concurrent use with ritonavir-based regimens, including lopinavir/ritonavir.</td>
</tr>
<tr>
<td>Proton Pump Inhibitors such as omeprazole, esomeprazole, lanosoprazole, rabeprazole, pantoprazole</td>
<td>Significant reductions in atazanavir plasma concentrations</td>
<td>Avoid concurrent use with atazanavir; consider use of an H2 receptor antagonist separated by at least 12 hours from atazanavir administration.</td>
</tr>
</tbody>
</table>

Adapted from reference 19, 21

Drugs for erectile dysfunction, such as sildenafil, vardenafil and the recently approved tadalafl, can also have their levels increased significantly by concurrent PI use. Specifically, sildenafil levels can be increased from two to eleven-fold when used concurrently with PI therapy. Therefore, clinicians should prescribe, at most, 25mg every 48 hours initially. For patients who do not respond to 25mg, consideration for using higher doses should only be done with extreme caution. PIs can also increase vardenafil concentrations.

Current guidelines from the product labeling suggest that for patients on a PI-based regimen that does not include ritonavir, the maximum initial dose of vardenafil should be 2.5mg, without repeating the dose for 24 hours. For patients receiving ritonavir even at low doses, the maximum initial vardenafil dose should be 2.5mg and should not be repeated for 72 hours. Tadalafil was also recently approved; maximum doses used should not exceed 10mg every 72 hours for patients receiving concurrent PI therapy.

Possible toxicities from these drugs include priapism, hypotension, and visual color changes.
Clinically Significant Drug Interactions... (continued from page 5)

HIV-infected patients may either have a seizure disorder or may require seizure prophylaxis due to OIs that involve the central nervous system. This often becomes problematic in the setting of HAART due to very limited data on concurrent use of anticonvulsants and PIs. Use of the anticonvulsants phenytoin, phenobarbital, and carbamazepine is of particular concern as they induce CYP450 enzymes that may lead to reduced PI or NNRTI levels. In fact, one case report in the literature describes ART failure possibly related to carbamazepine. Although adequate levels are being attained. Consensus may also be an option to ensure that adequate anticonvulsant therapy should undergo periodic monitoring of anticonvulsant drug levels. For some PIs, therapeutic drug monitoring may also be an option to ensure that adequate levels are being attained. Consensus trough concentrations have been established and are available in the most recent revision of the federal Department of Health and Human Services Guidelines. Patients infected with HIV-1 may require antifungal therapy for such infections as cryptococcal meningitis, or candidiasis. With regard to PI drug interactions, the safest of the oral medications is fluconazole, as drug interactions are minimal. However, the azole antifungal ketoconazole is a potent CYP3A4 inhibitor and increases the level of drug exposure to saquinavir and amprenavir by 190% and 31%, respectively. Conversely, ritonavir and lopinavir/ritonavir have demonstrated a three-fold increase in ketoconazole levels when used concurrently. Therefore doses >200 mg/day of ketoconazole are not recommended when using these medications concurrently. In general, ketoconazole should be avoided with concurrent HAART. The newest azole antifungal, voriconazole, has significant activity against aspergillosis and candida albicans. Its use for treatment of candidiasis in HIV-infected patients has been established; however, drug interaction data only exist for concurrent use of indinavir, where no clinically significant interaction occurred. Although extrapolation to other PIs may be possible, until data are available, use of this azole with other PI-containing regimens (especially those that contain ritonavir) should be undertaken when an alternative azole cannot be used, and close monitoring for voriconazole toxicity, such as elevated transaminases and visual toxicity. One of the recently approved PIs for use in the U.S. is atazanavir. Drug interactions with atazanavir are very similar to the other PIs; however, some differences do exist. In particular, atazanavir is a pH-dependent medication, requiring an acidic environment for absorption. As a result, the use of drugs that may alter the gastric pH are likely to be problematic. Since antacids may reduce atazanavir absorption, atazanavir should be administered two hours before or one hour after antacids. Proton pump inhibitors (PPIs) such as lansoprazole and omeprazole significantly alter the gastric pH for prolonged periods of time (often lasting longer than 24 hours), the atazanavir product labeling recommends that PPIs should not be used concurrently with atazanavir. As an alternative, providers may consider the use of a once daily histamine-2 (H-2) receptor antagonist separated by 12 hours from atazanavir. The current thought is that H2 blockers provide less prolonged suppression of acid, and, if separated, the interaction should be minimized. However, no data exist to prove or refute this theory. Other significant drug interactions may also occur with concurrent PI use. Table 3 summarizes medications that should generally be avoided with concurrent PI therapy.

Conclusions

Drug interactions are often complex and may be difficult to predict due to limited studies. Providers should be diligent in educating themselves about routes of metabolism for HAART and commonly prescribed medications to help recognize potential medications that may be problematic. As therapy for HIV changes very rapidly, providers may utilize internet resources to help screen for potential drug interactions and to identify new treatment options and issues surrounding HIV infection (See Resources on p.8). With such interventions, toxicity or adverse events associated with drug interactions may be prevented.
Drug Interactions with HAART and Methadone

<table>
<thead>
<tr>
<th>DRUG</th>
<th>EFFECT OF ANTIRETROViral THERAPY ON METHADONE</th>
<th>EFFECT OF METHADONE ON ANTIRETROViral THERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NUCLEOSIDE/NUCLEOTIDE ANALOGUES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abacavir</td>
<td>Decreased methadone clearance 25%</td>
<td>Decreased abacavir peak concentration 34%</td>
</tr>
<tr>
<td>Didanosine, buffered tablet</td>
<td>Unknown</td>
<td>Decreased didanosine AUC 57%</td>
</tr>
<tr>
<td>Didanosine, enteric-coated capsule</td>
<td>Unknown</td>
<td>No significant change in didanosine AUC 61%</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>Unknown</td>
<td>No significant change when given as</td>
</tr>
<tr>
<td></td>
<td></td>
<td>zidovudine-lamivudine</td>
</tr>
<tr>
<td>Stavudine</td>
<td>Unknown</td>
<td>Decreased stavudine AUC 23%</td>
</tr>
<tr>
<td>Tenofovir disoproxil fumarate</td>
<td>Unknown</td>
<td>No significant change in tenofovir DF</td>
</tr>
<tr>
<td>Zalcitabine</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Zidovudine</td>
<td>Unknown</td>
<td>Increased zidovudine AUC 41%</td>
</tr>
<tr>
<td><strong>NON NUCLEOSIDE ANALOGUES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delavirdine</td>
<td>Unknown, although potential increased</td>
<td>No change in delavirdine or N-delavirdine</td>
</tr>
<tr>
<td></td>
<td>methadone effect</td>
<td></td>
</tr>
<tr>
<td>Efavirenz</td>
<td>Decreased methadone levels 57%</td>
<td>Unknown</td>
</tr>
<tr>
<td>Nevirapine</td>
<td>Decreased methadone levels 51%</td>
<td>Unknown</td>
</tr>
<tr>
<td><strong>PROTEASE INHIBITORS (PIS)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amprenavir</td>
<td>Decreased methadone AUC 35%</td>
<td>Decreased amprenavir AUC, Cmax, Cmin</td>
</tr>
<tr>
<td>Indinavir</td>
<td>No significant change in methadone AUC</td>
<td>Insignificant change in indinavir AUC;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>increased indinavir Cmin 50%-100%;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>decreased indinavir Cmax 16%-36%</td>
</tr>
<tr>
<td>Lopinavir-ritonavir</td>
<td>Decreased methadone AUC 36%</td>
<td>Unknown</td>
</tr>
<tr>
<td>Nelfinavir</td>
<td>Decreased methadone AUC 40%</td>
<td>Decreased nelfinavir metabolite (M8) AUC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>53%; clinical significance unknown</td>
</tr>
<tr>
<td>Ritonavir</td>
<td>Decreased methadone AUC 36%</td>
<td>Unknown</td>
</tr>
<tr>
<td>Saquinavir, hard-gel capsule</td>
<td>Unknown with saquinavir as sole PI</td>
<td>Unknown with saquinavir as sole PI</td>
</tr>
<tr>
<td>Saquinavir, soft-gel capsule</td>
<td>Unknown with saquinavir as sole PI; unbound methadone concentrations unchanged when using saquinavir and ritonavir concurrently</td>
<td></td>
</tr>
</tbody>
</table>

AUC, area under the concentration time curve; Cmax, maximum drug concentration or peak level; Cmin, minimum drug concentration or trough level.


Clinically Significant Drug Interactions... (continued from page 6)

SAVE THE DATES

Using Enfuvirtide (T20) in Clinical Care
January 15, 2004
Boston, Massachusetts
Seminar topics will include: Antiretroviral Drugs; Drug Resistance; HIV/AIDS Treatment or Therapies
Sponsored by The New England AIDS Education and Training Center (NEAETC).
Call: 617.262-5657
Visit: www.neaetc.org

The 11th Conference on Retroviruses and Opportunistic Infection
February 8-11, 2004
San Francisco, California
Contact: Office of the Retrovirus Conference Secretariat
Call: 703.535.6862
Fax: 703.535.6899
Email: info@retroconference.org
Visit: www.retroconference.org

8th North American Region Conference of the International Union Against Tuberculosis and Lung Disease
February 26-28, 2003
Austin, Texas
Themes will include Global Threats to Regional TB; Cross-Border TB Issues; Treatment Strategies and Disparities of TB Control in Low-Incident Countries; and Scientific Challenges for TB Control: Resistance, Drug Discovery, and Laboratory Methods.
Call: 312.243.2000; Fax: 312.243.3954; TB@alamc.org; www.lungchicago.org or www.iuatld.org.

Management of HIV/AIDS in the Correctional Setting:
A Live Satellite Videoconference Series
Albany Medical Center
March 16, 2004
12:30 PM - 3:30 PM EST
CME and Nursing credits available
Call: 518.262.4674
Email: ybarraj@mail.amc.edu
To register as a site in your area visit www.amc.edu/Patient/hiv/hivconf/index.htm.

INSIDE NEWS

Rise in Syphilis Among MSM in San Francisco Linked to Internet
The internet is a major factor in San Francisco’s increase in early syphilis infections among men who have sex with men (MSM), according to a recent study from the CDC. A focus on data for 415 MSM diagnosed with early syphilis in 2002 found that internet chat rooms were the most common venues for meeting partners. Last year, the city reported the highest rates of first and second-stage syphilis of any metropolitan area in the nation. Between 1998-2002, early syphilis cases increased from 41 to 495. Officials noted at the time the proportion of cases among MSM had jumped from 22 percent in 1998 to 88 percent in 2002. However, the CDC and San Francisco Department of Public Health officials say that they have evidence that internet-based partner notification can be an effective tool for finding and treating early syphilis infections.


Bioequivalence study: 500 mg pill of Invirase
Two 200 mg formulations of Saquinavir (SQV) are currently marketed for oral administration in the treatment of HIV infection: Invirase, a hard gelatin capsule (saquinavir mesylate) and Fortovase, a soft gelatin capsule (saquinavir base). Both formulations have shown good efficacy and safety when boosted with ritonavir (r) in a SQV/r dosing of 1000/100 mg bid. The pill count for a SQV/r regimen using the current 200 mg formulation is 12 pills per day. Roche is developing a 500 mg saquinavir mesylate tablet that is smaller than the existing 200 mg formulation, allowing the use of only two SQV tablets twice daily in combination with ritonavir. The lower pill count and improved convenience may improve adherence to SQV/r regimens.

Boffito, Marta et al 9th EACS, October 2003, Warsaw, Poland. Oral Abstract

Study: Safety, Tolerability, and Efficacy of Interferon/Ribavirin Combination Therapy in Methadone Maintenance (MM) Patients with Active Hepatitis C (HCV)
In this study from the University of California, 78 percent of MM treated patients completed the six to 12 month course of interferon/ribavirin combination therapy. The end-of-treatment virologic response rate was 64% in patients completing treatment and 54% in an intent-to-treat analysis. Despite the fact that MM patients exhibit a number of factors that make HCV treatment challenging, such as older age, a higher prevalence of psychiatric illness, and more advanced liver disease, their end-of-treatment response rate to therapy is similar to that of patients without a history of IDU. These preliminary suggest that MM patients should be considered as potential candidates for HCV treatment.


Study: Gilead Announces Preliminary Results from 48-Week Phase III Study of Emtricitabine in Patients with Chronic Hepatitis B
Preliminary results from a Phase III clinical trial comparing the efficacy and safety of emtricitabine 200 mg once daily versus placebo in patients with chronic hepatitis B have been released. The results demonstrate improvements in liver histology in 62% of patients who received the drug compared to 25% of patients who received placebo (p less than 0.001). Improvement in liver histology was the primary endpoint in this study. Gilead expects to present these data in detail at a scientific conference next year.

www.natap.org 11/26/03

New CDC HIV Prevention Funding Emphasizes Effectiveness, Focuses on Those Already Infected
The federal Centers for Disease Control and Prevention (CDC) has announced $49 million in HIV prevention grants that require grantees to prove that their efforts are effective and focus more on doing prevention among people who are already infected with the virus. “The announcement included some specific items that are called program performance indicators;” said Dr. Harold W. Jaffe, director of CDC’s National Center for HIV, STD and TB Prevention. “They attempt to set goals.” The CDC expects to fund roughly 160 grants ranging in amounts from $100,000 to $500,000, according to the December 3, 2003 announcement. The grants will run for five years, but the $49 million represents only the first year’s funding.

HIV Update, 12/15/03

RESOURCES

www.hiv.medscape.com
New data from conferences, CE articles on HIV related topics and more.

www.aidsinfo.nih.gov
DHHS Guidelines for treatment of HIV infected adults, adolescents, children...

www.hivandhepatitis.com
Treatment/developments for Hepatitis A, B and C

www.hivcorrections.org
HIV clinical trials/developments and animation of viral life cycle that includes action of ART

www.hivguidelines.org
NYSDOH AIDS Institute Clinical Guidelines for adults, pediatrics, ART in adults, and more.
Self-Assessment Test for Continuing Medical Education Credit

Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through July 31, 2004. The estimated time for completion of this activity is one hour and there is no fee for participation.

1. The following two antiretroviral agents compete for the same phosphorylation site in the growing chain of HIV DNA, resulting in an antagonistic, pharmacodynamic interaction:
   (a) zidovudine and stavudine
   (b) zidovudine and didanosine
   (c) didanosine and stavudine
   (d) lamivudine and emtricitabine

2. The following antiretroviral agent contains magnesium and calcium and therefore interferes with the absorption of antibiotics such as ciprofloxacin, tetracycline and doxycycline.
   (a) zidovudine
   (b) didanosine
   (c) abacavir
   (d) tenofovir

3. Which of the following statements is true:
   (a) Nevirapine and efavirenz are, in general, inhibitors of CYP3A4, while delavirdine is an inducer of CYP3A4
   (b) when nevirapine is given concurrently with methadone, intoxication symptoms may occur as a result of increased methadone levels
   (c) When enteric-coated ddI is co-administered with tenofovir, the ddI AUC increases 60%.
   (d) Abacavir increases the metabolism of oral contraceptives and can lead to contraceptive failure; therefore providers should recommend alternate methods of birth control for patients receiving abacavir.

4. When used together with one of the following antiretrovirals, the AUC and Cmax of clarithromycin decreased 39% and 26%, respectively. Concurrent use of clarithromycin should therefore be avoided in patients receiving:
   (a) nelfinavir
   (b) efavirenz
   (c) lopinavir
   (d) abacavir

5. The concentrations of some “statins” are markedly increased by concurrent protease inhibitor therapy, placing the patient at risk for myopathy, rhabdomyolysis, and possibly renal failure and death.

Brown Medical School • Office of Continuing Medical Education • Box G-A2 • Providence, RI 02912

The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

The use of the Brown Medical School name implies review of the educational format and material only. The opinions, recommendations and editorial positions expressed by those whose input is included in this bulletin are their own. They do not represent or speak for the Brown Medical School.

For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.

Name ___________________________ Degree ___________________________

Address __________________________

City ___________________________ State _____ Zip ____________

Telephone ________________________ Fax ________________________

HEPP Report Evaluation

5 Excellent 4 Very Good 3 Fair 2 Poor 1 Very Poor

1. Please evaluate the following sections with respect to:
   educational value clarity

   Main Article 5 4 3 2 1  5 4 3 2 1
   Inside News 5 4 3 2 1  5 4 3 2 1
   Save the Dates 5 4 3 2 1  5 4 3 2 1

2. Do you feel that HEPP Report helps you in your work?
   Why or why not?

3. What future topics should HEPP Report address?

4. How can HEPP Report be made more useful to you?

5. Do you have specific comments on this issue?